Ten $1bn+ alliances were penned in January. Topping the list was a potential $5.2bn deal between Sanofi and Exscientia for the development of up to 15 novel small molecule candidates across oncology and immunology. The collaboration will leverage Exscientia’s AI-driven personalized medicine platform which enables a “patient-first” approach through integrating primary human tissue samples into early target and drug discovery research. Exscientia will lead small molecule drug design and lead optimization activities up to development candidate nomination, with Sanofi assuming responsibility for preclinical and clinical development, manufacturing and commercialization.
In the top January M&A by deal value, Samsung Biologics entered an agreement to acquire Biogen’s 49.9% equity stake in Samsung Bioepis for an aggregate consideration of up to $2.3bn. Established in 2021 as a joint venture between Samsung Biologics and Biogen, Samsung Bioepis is dedicated to advancing a broad pipeline of biosimilar candidates that cover a spectrum of therapeutic areas, including immunology, oncology and ophthalmology. Financing reached $8bn in biopharma, $771m in device, and $420m in diagnostics.
Pharma Intelligence
